AU2002254171A2 - RXR activating molecules - Google Patents

RXR activating molecules Download PDF

Info

Publication number
AU2002254171A2
AU2002254171A2 AU2002254171A AU2002254171A AU2002254171A2 AU 2002254171 A2 AU2002254171 A2 AU 2002254171A2 AU 2002254171 A AU2002254171 A AU 2002254171A AU 2002254171 A AU2002254171 A AU 2002254171A AU 2002254171 A2 AU2002254171 A2 AU 2002254171A2
Authority
AU
Australia
Prior art keywords
substituted
alkyl
residue
amino
alkoxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2002254171A
Other languages
English (en)
Inventor
Hussien A. Al-Shamma
Andrea Fanjul
Richard Fine
Jianhua Guo
Karine Jakubowicz-Jaillardon
Magnus Pfahl
David P. M. Pleynet
Lyle W. Spruce
Catherine Tachdjian
James W. Zapf
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Incyte San Diego Inc
Original Assignee
Incyte San Diego Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Incyte San Diego Inc filed Critical Incyte San Diego Inc
Publication of AU2002254171A2 publication Critical patent/AU2002254171A2/en
Assigned to INCYTE SAN DIEGO, INC. reassignment INCYTE SAN DIEGO, INC. Amend patent request/document other than specification (104) Assignors: MAXIA PHARMACEUTICALS, INC.
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/06—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
    • C07D271/07—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles with oxygen, sulfur or nitrogen atoms, directly attached to ring carbon atoms, the nitrogen atoms not forming part of a nitro radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Solid-Sorbent Or Filter-Aiding Compositions (AREA)
  • Peptides Or Proteins (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2002254171A 2001-03-08 2002-03-08 RXR activating molecules Abandoned AU2002254171A2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US27434201P 2001-03-08 2001-03-08
US60/274,342 2001-03-08
PCT/US2002/007342 WO2002072543A2 (en) 2001-03-08 2002-03-08 Rxr activating molecules

Publications (1)

Publication Number Publication Date
AU2002254171A2 true AU2002254171A2 (en) 2002-09-24

Family

ID=23047783

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2002254171A Abandoned AU2002254171A2 (en) 2001-03-08 2002-03-08 RXR activating molecules

Country Status (6)

Country Link
US (2) US7265139B2 (enExample)
EP (1) EP1377559A4 (enExample)
JP (1) JP2004523571A (enExample)
AU (1) AU2002254171A2 (enExample)
CA (1) CA2473156A1 (enExample)
WO (1) WO2002072543A2 (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1384825A (zh) * 1999-08-31 2002-12-11 马克西亚药品公司 亚苄基－噻唑烷二酮及其类似物以及它们在治疗糖尿病中的应用
BR0207846A (pt) 2001-03-07 2005-09-13 Incyte San Diego Inc Derivados heterocìclicos para o tratamento de câncer e outras doenças proliferativas
JP2004523571A (ja) 2001-03-08 2004-08-05 マキシア・ファーマシューティカルズ・インコーポレイテッド Ｒｘｒ活性化分子
EP1421061A4 (en) * 2001-08-17 2004-12-22 Incyte San Diego Inc OXIME DERIVATIVES FOR THE TREATMENT OF DYSLIPIDEMIA AND HYPERCHOLESTEROLEMIA
JP2005513026A (ja) * 2001-11-15 2005-05-12 インサイト サン ディエゴ インコーポレイテッド 高コレステロール血症、異脂肪血症および他の代謝障害；癌、および他の疾患を治療するｎ−置換複素環
US7102000B2 (en) 2002-03-08 2006-09-05 Incyte San Diego Inc. Heterocyclic amide derivatives for the treatment of diabetes and other diseases
US7196108B2 (en) 2002-03-08 2007-03-27 Incyte San Diego Inc. Bicyclic heterocycles for the treatment of diabetes and other diseases
BRPI0409501A (pt) * 2003-04-18 2006-04-18 Incyte San Diego Inc compostos isocromanos substituìdos para o tratamento de desordens metabólicas, de cáncer e de outras doenças
WO2005100396A1 (en) * 2004-04-16 2005-10-27 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with retinoid x receptor alpha (rxra)
WO2005101006A2 (en) * 2004-04-16 2005-10-27 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with retinoid x receptor beta (rxrb)
CN101316821A (zh) * 2005-09-30 2008-12-03 詹森药业有限公司 作为rxr激动剂用于治疗异常脂肪血症、高胆固醇血症和糖尿病的二氢-[1h]-喹啉-2-酮衍生物
ES2569660T3 (es) 2007-06-08 2016-05-12 Mannkind Corporation Inhibidores de la IRE-1alfa
WO2010032582A1 (ja) * 2008-09-22 2010-03-25 国立大学法人鹿児島大学 成人ｔ細胞白血病治療薬
WO2010074807A1 (en) * 2008-10-30 2010-07-01 Gilead Palo Alto, Inc. 3, 4-dihydroquinolin-2 ( 1h ) -one derivatives as sodium channel modulators
CR20200464A (es) 2018-03-08 2021-04-14 Incyte Corp Compuestos diólicos de aminopirazina como inhibidores de pi3k-y
WO2020010003A1 (en) 2018-07-02 2020-01-09 Incyte Corporation AMINOPYRAZINE DERIVATIVES AS PI3K-γ INHIBITORS
CN109628328B (zh) * 2019-01-11 2022-02-15 河南省农业科学院植物保护研究所 一株能够防治芝麻枯萎病且具有促生和诱导抗性作用的拜赖青霉及其筛选方法和应用

Family Cites Families (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4051842A (en) * 1975-09-15 1977-10-04 International Medical Corporation Electrode and interfacing pad for electrical physiological systems
DE2626348C3 (de) * 1976-06-11 1980-01-31 Siemens Ag, 1000 Berlin Und 8000 Muenchen Implantierbare Dosiereinrichtung
JPS5538359A (en) 1978-09-12 1980-03-17 Hamari Yakuhin Kogyo Kk Preparation of 2-(3-benzoylphenyl)-propionic acid
US4383529A (en) * 1980-11-03 1983-05-17 Wescor, Inc. Iontophoretic electrode device, method and gel insert
IL72684A (en) * 1984-08-14 1989-02-28 Israel State Pharmaceutical compositions for controlled transdermal delivery of cholinergic or anticholinergic basic drugs
US4713244A (en) * 1985-08-16 1987-12-15 Bausch & Lomb Incorporated Sustained-release formulation containing an amino acid polymer with a lower alkyl (C1 -C4) polar solvent
US4931279A (en) * 1985-08-16 1990-06-05 Bausch & Lomb Incorporated Sustained release formulation containing an ion-exchange resin
US4668506A (en) * 1985-08-16 1987-05-26 Bausch & Lomb Incorporated Sustained-release formulation containing and amino acid polymer
CA1325222C (en) 1985-08-23 1993-12-14 Lederle (Japan), Ltd. Process for producing 4-biphenylylacetic acid
DE3874257T2 (de) * 1987-03-11 1993-02-11 Kanegafuchi Chemical Ind Hydroxystyren-derivate.
FI91869C (fi) * 1987-03-18 1994-08-25 Tanabe Seiyaku Co Menetelmä antidiabeettisena aineena käytettävien bensoksatsolijohdannaisten valmistamiseksi
JPS63230689A (ja) * 1987-03-18 1988-09-27 Tanabe Seiyaku Co Ltd ベンゾオキサジン誘導体
US5330998A (en) * 1988-03-08 1994-07-19 Pfizer Inc. Thiazolidinedione derivatives as hypoglycemic agents
US5223522A (en) * 1988-03-08 1993-06-29 Pfizer Inc. Thiazolidinedione hypoglycemic agents
IE940525L (en) 1988-05-25 1989-11-25 Warner Lambert Co Known and selected novel arylmethylenyl derivatives of¹thiazolidinones, imidazolidinones and oxazolidinones useful¹as antiallergy agents and antiinflammatory agents
EP0595868B1 (en) * 1991-07-22 1998-11-25 Pfizer Inc. Process for the preparation of (s)-4-[3-(5-methyl-2-phenyl-4-oxazolyl)- 1-hydroxypropyl]bromobenzene
US5573905A (en) * 1992-03-30 1996-11-12 The Scripps Research Institute Encoded combinatorial chemical libraries
US5780676A (en) * 1992-04-22 1998-07-14 Ligand Pharmaceuticals Incorporated Compounds having selective activity for Retinoid X Receptors, and means for modulation of processes mediated by Retinoid X Receptors
DE69333894D1 (de) 1992-04-22 2005-12-01 Ligand Pharm Inc Verbindungen mit Retinoid x rezeptorselektivität
CZ181493A3 (en) * 1992-09-10 1994-03-16 Lilly Co Eli The use of rhodanine derivative for the preparation of a pharmaceutical composition reducing level of sugar in blood and for treating alzheimer's disease
US5565324A (en) * 1992-10-01 1996-10-15 The Trustees Of Columbia University In The City Of New York Complex combinatorial chemical libraries encoded with tags
WO1994012880A2 (en) * 1992-11-25 1994-06-09 La Jolla Cancer Research Foundation Rxr homodimer formation and bridged bicyclic aromatic compounds and their use in modulating gene expression
ES2130597T3 (es) * 1994-02-17 1999-07-01 American Home Prod Derivados de bifenilo sustituido como inhibidores de la fosfodiesterasa.
US5691376A (en) * 1994-02-17 1997-11-25 American Home Products Corporation Substituted biphenyl derivatives
JPH09136877A (ja) 1995-06-16 1997-05-27 Takeda Chem Ind Ltd 複素環化合物、その製造法及び用途
CA2223489A1 (en) 1995-07-17 1997-02-06 Joseph A. Fontana Method for treating cancer using ahpn
WO1997027191A1 (en) 1996-06-19 1997-07-31 Dr. Reddy's Research Foundation Novel polymorphic forms of troglitazone having enhanced anti-diabetic activity and a process for their preparation
US6127415A (en) * 1996-07-08 2000-10-03 Galderma Research & Development, S.N.C. Apoptosis inducing adamantyl derivatives and their usage as anti-cancer agents
CA2300813A1 (en) 1997-08-21 1999-03-04 Hiroyuki Odaka Anti-inflammatory agent
US6168913B1 (en) * 1997-10-14 2001-01-02 Abbott Laboratories Coding combinatorial libraries with fluorine tags
EP1048659A4 (en) 1997-11-12 2002-11-20 Inst Med Molecular Design Inc Retinoid receptor Antagonist
US6087103A (en) * 1998-03-04 2000-07-11 Lifespan Biosciences, Inc. Tagged ligand arrays for identifying target-ligand interactions
US6262044B1 (en) * 1998-03-12 2001-07-17 Novo Nordisk A/S Modulators of protein tyrosine phosphatases (PTPASES)
US6331633B1 (en) 1998-05-08 2001-12-18 Calyx Therapeutics Inc. Heterocyclic analogs of diphenylethylene compounds
IL141456A0 (en) 1998-08-21 2002-03-10 Viropharma Inc Rhodanine derivatives and pharmaceutical compositions containing the same
WO2000018748A1 (en) 1998-09-30 2000-04-06 Roche Diagnostics Gmbh Rhodanine derivatives for the treatment and prevention of metabolic bone disorders
AU3111700A (en) 1998-12-04 2000-06-19 Structural Bioinformatics Inc. Methods and compositions for treating inflammatory diseases utilizing inhibitorsof tumor necrosis factor activity
AU3958200A (en) * 1999-04-20 2000-11-02 Novo Nordisk A/S New compounds, their preparation and use
US6462032B1 (en) 1999-05-04 2002-10-08 Wyeth Cyclic regimens utilizing indoline derivatives
CN1384825A (zh) * 1999-08-31 2002-12-11 马克西亚药品公司 亚苄基－噻唑烷二酮及其类似物以及它们在治疗糖尿病中的应用
PT1142885E (pt) 1999-11-12 2007-02-28 Fujimoto Brothers Co Ltd Derivados de 2-(n-cianoimino)tiazolidin-4-ona
FR2812876B1 (fr) * 2000-08-08 2002-09-27 Galderma Res & Dev Nouveaux composes bi-aromatiques activateurs des recepteurs de type ppar-gamma et leur utilisation dans des compositions cosmetiques ou pharmaceutiques
BR0207846A (pt) * 2001-03-07 2005-09-13 Incyte San Diego Inc Derivados heterocìclicos para o tratamento de câncer e outras doenças proliferativas
JP2004523571A (ja) 2001-03-08 2004-08-05 マキシア・ファーマシューティカルズ・インコーポレイテッド Ｒｘｒ活性化分子
AU2002258550B2 (en) 2001-03-14 2006-04-27 Eli Lilly And Company Retinoid X receptor modulators
JP4590158B2 (ja) 2001-04-04 2010-12-01 オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド グルコース再吸収阻害剤およびレチノイド−ｘ受容体モジュレーターを含んで成る併用療法
EP1421061A4 (en) * 2001-08-17 2004-12-22 Incyte San Diego Inc OXIME DERIVATIVES FOR THE TREATMENT OF DYSLIPIDEMIA AND HYPERCHOLESTEROLEMIA
JP2005513026A (ja) * 2001-11-15 2005-05-12 インサイト サン ディエゴ インコーポレイテッド 高コレステロール血症、異脂肪血症および他の代謝障害；癌、および他の疾患を治療するｎ−置換複素環
TW200304375A (en) * 2001-12-06 2003-10-01 Maxia Pharmaceuticals Inc 2-Substituted thiazolidinone and oxazolidinone derivatives for the inhibition of phosphatases and the treatment of cancer
US7102000B2 (en) * 2002-03-08 2006-09-05 Incyte San Diego Inc. Heterocyclic amide derivatives for the treatment of diabetes and other diseases
US7196108B2 (en) * 2002-03-08 2007-03-27 Incyte San Diego Inc. Bicyclic heterocycles for the treatment of diabetes and other diseases
US20050014767A1 (en) * 2003-01-29 2005-01-20 Magnus Pfahl Benzoxazole, benzothiazole, and benzimidazole derivatives for the treatment of cancer and other diseases
BRPI0409501A (pt) * 2003-04-18 2006-04-18 Incyte San Diego Inc compostos isocromanos substituìdos para o tratamento de desordens metabólicas, de cáncer e de outras doenças

Also Published As

Publication number Publication date
EP1377559A2 (en) 2004-01-07
CA2473156A1 (en) 2002-09-19
WO2002072543A3 (en) 2003-03-13
WO2002072543A2 (en) 2002-09-19
US7265139B2 (en) 2007-09-04
US20030105333A1 (en) 2003-06-05
EP1377559A4 (en) 2005-09-28
JP2004523571A (ja) 2004-08-05
US20050209286A1 (en) 2005-09-22

Similar Documents

Publication Publication Date Title
US7265139B2 (en) RXR activating molecules
Thangavel et al. Targeting peroxisome proliferator‐activated receptors using thiazolidinediones: strategy for design of novel antidiabetic drugs
Sznaidman et al. Novel selective small molecule agonists for peroxisome proliferator-activated receptor δ (PPARδ)—synthesis and biological activity
Liu et al. Novel coumarin-thiazolyl ester derivatives as potential DNA gyrase Inhibitors: Design, synthesis, and antibacterial activity
KR100706735B1 (ko) ｈＰＰＡＲ 알파 활성제로서 치환된 옥사졸 및 티아졸유도체
Szczepankiewicz et al. Discovery of a potent, selective protein tyrosine phosphatase 1B inhibitor using a linked-fragment strategy
JP5068768B2 (ja) １１ベータ−ｈｓｄ１阻害剤としてのチアゾール
Mahindroo et al. Novel indole-based peroxisome proliferator-activated receptor agonists: design, SAR, structural biology, and biological activities
CA2457054C (en) Activator of peroxisome proliferator-activated receptor .delta.
KR20010034586A (ko) 카르복실산 유도체와 그 유도체를 유효 성분으로서함유하는 약제
KR20090006853A (ko) 페록시좀 증식제 활성화 수용체 δ 의 활성화제
CA2382581C (en) Substituted benzylthiazolidine-2,4-dione derivatives
Inoue et al. Novel 1H-imidazol-2-amine derivatives as potent and orally active vascular adhesion protein-1 (VAP-1) inhibitors for diabetic macular edema treatment
Patchipala et al. Synthesis, in-vivo anti-diabetic & anticancer activities and molecular modelling studies of tetrahydrobenzo [d] thiazole tethered nicotinohydrazide derivatives
DE60130031T2 (de) Dihydronaphthalinderivat verbindungen und arzneimittel, die diese verbindungen als wirkstoff enthalten
US6768008B2 (en) Materials and methods for the treatment of diabetes, hyperlipidemia, hypercholesterolemia, and atherosclerosis
CN106928147A (zh) 三环二萜类似物及其制备方法、及其在制备抗前列腺癌药物中的应用
Singh et al. Design, synthesis, and molecular modeling of heterodimer and inhibitors of α-amylase as hypoglycemic agents
WO2000023442A1 (en) Carboxylic acid derivatives and drugs containing the same as the active ingredient
Furukawa et al. Synthesis and biological evaluation of novel (−)-cercosporamide derivatives as potent selective PPARγ modulators
Haroun In silico design, synthesis and evaluation of novel series of benzothiazole-based pyrazolidinediones as potent hypoglycemic agents
Yang et al. Synthesis of 2‑Fluoroalkylated Oxazoles from β‑Monosubstituted Enamines via Fluoroacyloxylation and Cyclization Mediated by Fluoroalkyl-Containing Hypervalent Iodine (III) Species Generated In Situ
WO2004080947A1 (ja) イミノエーテル誘導体化合物およびその化合物を有効成分として含有する薬剤
Srinivas et al. Development of novel glitazones as antidiabetic agents: molecular design, synthesis, evaluation of glucose uptake activity and SAR studies
Sun et al. Design, Synthesis, and Biological Evaluation of Novel C14− C3′ BzN-Linked Macrocyclic Taxoids

Legal Events

Date Code Title Description
DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS: ADD CO-INVENTORS JAKUBOWICZ-JAILLARDON, KARINE AND GUO, JIANHUA.

DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 24 SEP 2003

MK4 Application lapsed section 142(2)(d) - no continuation fee paid for the application